Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cell Death and Disease

Topics

Biology

Biochemistry

Chemistry

Immunology

Molecular Biology

Show all topics

DOI

10.1038/cddis.2014.561

License

CC-BY

Other Formats

PDF